Crews Bank & Trust Acquires Shares of 107 Stryker Co. (NYSE:SYK)

Crews Bank & Trust bought a new position in Stryker Co. (NYSE:SYK) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 107 shares of the medical technology company’s stock, valued at approximately $39,000.

Several other hedge funds and other institutional investors have also modified their holdings of SYK. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Stryker during the 3rd quarter valued at about $36,000. Hara Capital LLC acquired a new position in Stryker in the third quarter valued at about $42,000. HBW Advisory Services LLC bought a new stake in Stryker during the third quarter worth about $42,000. Finally, Grove Bank & Trust raised its stake in shares of Stryker by 84.8% in the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 56 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.1 %

Stryker stock opened at $390.90 on Friday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The firm has a market capitalization of $149.02 billion, a price-to-earnings ratio of 50.37, a PEG ratio of 2.68 and a beta of 0.95. The company’s 50 day simple moving average is $376.68 and its 200 day simple moving average is $362.81.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same period last year, the business posted $3.46 earnings per share. As a group, sell-side analysts anticipate that Stryker Co. will post 13.53 EPS for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date was Tuesday, December 31st. Stryker’s dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Wednesday. Truist Financial upped their price target on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday. The Goldman Sachs Group raised their price objective on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, UBS Group increased their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $419.37.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.